Tom 3, Nr 3 (2022)
Wytyczne / stanowisko ekspertów
Wysłany: 2022-09-27
Zaakceptowany: 2022-09-27
Opublikowany online: 2023-01-13
Pobierz cytowanie

Wytyczne Polskiego Towarzystwa Chorób Płuc dotyczące diagnostyki i leczenia choroby śródmiąższowej płuc z postępującym włóknieniem, innej niż idiopatyczne włóknienie płuc

Polskie Towarzystwo Chorób Płuc
Pneum Pol 2022;3(3):55-75.

dostęp płatny

Tom 3, Nr 3 (2022)
WYTYCZNE I REKOMENDACJE
Wysłany: 2022-09-27
Zaakceptowany: 2022-09-27
Opublikowany online: 2023-01-13

Streszczenie

Brak

Streszczenie

Brak
Pobierz cytowanie
Informacje o artykule
Tytuł

Wytyczne Polskiego Towarzystwa Chorób Płuc dotyczące diagnostyki i leczenia choroby śródmiąższowej płuc z postępującym włóknieniem, innej niż idiopatyczne włóknienie płuc

Czasopismo

Pneumonologia Polska

Numer

Tom 3, Nr 3 (2022)

Typ artykułu

Wytyczne / stanowisko ekspertów

Strony

55-75

Opublikowany online

2023-01-13

Wyświetlenia strony

41

Wyświetlenia/pobrania artykułu

7

Rekord bibliograficzny

Pneum Pol 2022;3(3):55-75.

Autorzy

Polskie Towarzystwo Chorób Płuc

Referencje (130)
  1. Travis WD, Costabel U, Hansell DM, et al. ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013; 188(6): 733–748.
  2. Kolb M, Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019; 20(1): 57.
  3. Brown KK, Martinez FJ, Walsh SLF, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020; 55(6).
  4. George PM, Spagnolo P, Kreuter M, et al. Erice ILD working group. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020; 8(9): 925–934.
  5. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018; 198(5): e44–68.
  6. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018; 378(19): 1811–1823.
  7. Piotrowski WJ, Bestry I, Białas AJ, et al. Guidelines of the Polish Respiratory Society for diagnosis and treatment of idiopathic pulmonary fibrosis. Adv Respir Med. 2020; 88(1): 41–93.
  8. Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010; 35(3): 496–504.
  9. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. The Lancet. 2017; 389(10082): 1941–52.
  10. Kwon BS, Choe J, Chae EJ, et al. Progressive fibrosing interstitial lung disease: prevalence and clinical outcome. Respir Res. 2021; 22(1): 282.
  11. Faverio P, Piluso M, De Giacomi F, et al. Progressive fibrosing interstitial lung diseases: Prevalence and characterization in two Italian referral centers. Respiration. 2020; 99(10): 838–845.
  12. Chiu YH, Spierings J, de Jong PA, et al. Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases. Respir Med. 2021; 187: 106579.
  13. Hyldgaard C, Ellingsen T, Hilberg O, et al. Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality. Respiration. 2019; 98(5): 455–460.
  14. Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019; 35(11): 2015–2024.
  15. Goos T, De Sadeleer LJ, Yserbyt J, et al. Defining and predicting progression in non-IPF interstitial lung disease. Respir Med. 2021; 189: 106626.
  16. Flaherty KR, Wells AU, Brown KK, et al. INBUILD Trial Investigators. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019; 381(18): 1718–1727.
  17. Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020; 8(2): 147–157.
  18. Wells AU, Flaherty KR, Brown KK, et al. INBUILD trial investigators. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020; 8(5): 453–460.
  19. Nunes H, Schubel K, Piver D, et al. Nonspecific interstitial pneumonia: survival is influenced by the underlying cause. Eur Respir J. 2015; 45(3): 746–755.
  20. Gimenez A, Storrer K, Kuranishi L, et al. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax. 2018; 73(4): 391–392.
  21. Lee JiY, Jin SM, Lee BJ, et al. Treatment response and long term follow-up results of nonspecific interstitial pneumonia. J Korean Med Sci. 2012; 27(6): 661–667.
  22. Goh NS, Hoyles RK, Denton CP, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 2017; 69(8): 1670–1678.
  23. Distler O, Highland KB, Gahlemann M, et al. SENSCIS Trial Investigators. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019; 380(26): 2518–2528.
  24. Agencja Oceny Technologii Medycznych i Taryfikacji. Ramy metodyczne opracowywania zaleceń postępowania diagnostyczno-terapeutycznego. 2017.
  25. Schünemann HJ, Jaeschke R, Cook DJ, et al. ATS Documents Development and Implementation Committee. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med. 2006; 174(5): 605–614.
  26. Narzędzie oceny wytycznych AGREE II.
  27. Funke-Chambour M, Azzola A, Adler D, et al. Idiopathic pulmonary fibrosis in Switzerland: diagnosis and treatment. Respiration. 2017; 93(5): 363–378.
  28. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022; 205(9): e18–e47.
  29. Wells AU, Brown KK, Flaherty KR, et al. IPF Consensus Working Group. What's in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018; 51(5).
  30. Cottin V, Wollin L, Fischer A, et al. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019; 28(151).
  31. Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res. 2017; 4(1): e000212.
  32. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005; 26(5): 948–968.
  33. Oldham JM, Lee CT, Wu Z, et al. Lung function trajectory in progressive fibrosing interstitial lung disease. Eur Respir J. 2022; 59(6).
  34. Fernández Pérez ER, Swigris JJ, Forssén AV, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest. 2013; 144(5): 1644–1651.
  35. Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018; 27(150).
  36. Raghu G, Wells AU, Nicholson AG, et al. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med. 2017; 195(1): 78–85.
  37. Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017; 72(4): 340–346.
  38. Albera C, Costabel U, Fagan EA, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016; 48(3): 843–851.
  39. Vasakova M, Morell F, Walsh S, et al. Hypersensitivity Pneumonitis: perspectives in diagnosis and management. Am J Respir Crit Care Med. 2017; 196(6): 680–689.
  40. Kaul B, Cottin V, Collard HR, et al. Variability in global prevalence of interstitial lung disease. Front Med (Lausanne). 2021; 8: 751181.
  41. Opinc AH, Makowska JS. Antisynthetase syndrome - much more than just a myopathy. Semin Arthritis Rheum. 2021; 51(1): 72–83.
  42. Agmon-Levin N, Damoiseaux J, Kallenberg C, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014; 73(1): 17–23.
  43. Bertolazzi C, Vargas Guerrero A, Rodríguez-Reyna TS, et al. PANLAR Capillaroscopy Study Group (GECAP). Pan-American League of Associations for Rheumatology (PANLAR) capillaroscopy study group consensus for the format and content of the report in capillaroscopy in rheumatology. Clin Rheumatol. 2019; 38(9): 2327–2337.
  44. Sambataro D, Sambataro G, Pignataro F, et al. Patients with interstitial lung disease secondary to autoimmune diseases: how to recognize them? Diagnostics (Basel). 2020; 10(4).
  45. Behr J, Günther A, Ammenwerth W, et al. German guideline for diagnosis and management of idiopathic pulmonary fibrosis. Pneumol Stuttg Ger. 2013; 67(2): 81–111.
  46. Cottin V, Crestani B, Valeyre D, et al. French National Reference and Competence Centers for Rare Diseases, Societe de Pneumologies de Langue Francaise. [French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. From the National Reference and the Competence centers for rare diseases and the Société de Pneumologie de Langue Française]. Rev Mal Respir. 2013; 30(10): 879–902.
  47. Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018; 6(2): 138–153.
  48. Prasad JD, Mahar A, Bleasel J, et al. The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology. 2017; 22(7): 1459–1472.
  49. Singh S, Collins BF, Sharma BB, et al. Interstitial lung disease in India. Results of a prospective registry. Am J Respir Crit Care Med. 2017; 195(6): 801–813.
  50. Chaudhuri N, Spencer L, Greaves M, et al. A review of the multidisciplinary diagnosis of interstitial lung diseases: A retrospective analysis in a single UK specialist centre. J Clin Med. 2016; 5(8).
  51. Thomeer M, Demedts M, Behr J, et al. Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study group. Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J. 2008; 31(3): 585–591.
  52. Jo HE, Glaspole IN, Levin KC, et al. Clinical impact of the interstitial lung disease multidisciplinary service. Respirology. 2016; 21(8): 1438–1444.
  53. Theegarten D, Müller HM, Bonella F, et al. Diagnostic approach to interstitial pneumonias in a single centre: report on 88 cases. Diagn Pathol. 2012; 7: 160.
  54. Flaherty KR, King TE, Raghu G, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004; 170(8): 904–910.
  55. Flaherty KR, Andrei AC, King TE, et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med. 2007; 175(10): 1054–1060.
  56. Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. Eur Respir J. 2017; 50(2).
  57. Richeldi L, Launders N, Martinez F, et al. The characterisation of interstitial lung disease multidisciplinary team meetings: a global study. ERJ Open Res. 2019; 5(2).
  58. Levi Y, Israeli-Shani L, Kuchuk M, et al. Rheumatological assessment is important for interstitial lung disease diagnosis. J Rheumatol. 2018; 45(11): 1509–1514.
  59. De Sadeleer LJ, Meert C, Yserbyt J, et al. Diagnostic ability of a dynamic multidisciplinary discussion in interstitial lung diseases: A retrospective observational study of 938 cases. Chest. 2018; 153(6): 1416–1423.
  60. Castelino FV, Goldberg H, Dellaripa PF. The impact of rheumatological evaluation in the management of patients with interstitial lung disease. Rheumatology (Oxford). 2011; 50(3): 489–493.
  61. Behr J, Günther A, Bonella F, et al. German guideline for idiopathic pulmonary fibrosis – update on pharmacological therapies 2017. Pneumologie. 2018; 72(02): 155–168.
  62. Chung JH, Lynch DA. The value of a multidisciplinary approach to the diagnosis of usual interstitial pneumonitis and idiopathic pulmonary fibrosis: radiology, pathology, and clinical correlation. AJR Am J Roentgenol. 2016; 206(3): 463–471.
  63. Behr J, Neuser P, Prasse A, et al. Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulm Med. 2017; 17(1): 122.
  64. Hoffmann-Vold AM, Allanore Y, Alves M, et al. EUSTAR collaborators. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021; 80(2): 219–227.
  65. Nasser M, Larrieu S, Si-Mohamed S, et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur Respir J. 2021; 57(2).
  66. Damoiseaux J, Vulsteke JB, Tseng CW, et al. Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays. Autoimmun Rev. 2019; 18(3): 293–305.
  67. Cottin V, Larrieu S, Boussel L, et al. Epidemiology, mortality and healthcare resource utilization associated with systemic sclerosis-associated interstitial lung disease in France. Front Med (Lausanne). 2021; 8: 699532.
  68. Kawano-Dourado L, Baldi BG, Kay FU, et al. Pulmonary involvement in long-term mixed connective tissue disease: functional trends and image findings after 10 years. Clin Exp Rheumatol. 2015; 33(2): 234–240.
  69. Morisset J, Johnson C, Rich E, et al. Management of myositis-related interstitial lung disease. Chest. 2016; 150(5): 1118–1128.
  70. Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010; 62(6): 1583–1591.
  71. Luppi F, Sebastiani M, Silva M, et al. Interstitial lung disease in Sjögren's syndrome: a clinical review. Clin Exp Rheumatol. 2020; 38 Suppl 126(4): 291–300.
  72. Mittoo S, Fell CD. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med. 2014; 35(2): 249–254.
  73. Bosello SL, Beretta L, Del Papa N, et al. Interstitial lung disease associated with autoimmune rheumatic diseases: checklists for clinical practice. Front Med (Lausanne). 2021; 8: 732761.
  74. Elhai M, Meune C, Avouac J, et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012; 51(6): 1017–1026.
  75. Majewski S, Makowska J. Rheumatoid arthritis-associated interstitial lung disease – an underestimated, complex and interdisciplinary problem in everyday clinical practice. Medycyna Faktów. 2020; 13(4): 431–441.
  76. Hyldgaard C, Bendstrup E, Pedersen AB, et al. Interstitial lung disease in connective tissue diseases: survival patterns in a population-based cohort. J Clin Med. 2021; 10(21).
  77. Atzeni F, Gerardi MC, Barilaro G, et al. Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. Expert Rev Clin Immunol. 2018; 14(1): 69–82.
  78. Johannson K, Chaudhuri N, Adegunsoye A, et al. Treatment of fibrotic interstitial lung disease: current approaches and future directions. The Lancet. 2021; 398(10309): 1450–1460.
  79. Wollin L, Distler JHW, Redente EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019; 54(3).
  80. Gao Y, Moua T. Treatment of the connective tissue disease-related interstitial lung diseases: a narrative review. Mayo Clin Proc. 2020; 95(3): 554–573.
  81. Cottin V, Richeldi L, Rosas I, et al. INBUILD Trial Investigators. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respir Res. 2021; 22(1): 84.
  82. Cottin V. Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases. Eur Respir Rev. 2019; 28(153).
  83. Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. Respir Res. 2020; 21(1): 32.
  84. Collins BF, Luppi F. Diagnosis and management of fibrotic interstitial lung diseases. Clin Chest Med. 2021; 42(2): 321–335.
  85. Tashkin DP, Elashoff R, Clements PJ, et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006; 354(25): 2655–2666.
  86. Tashkin DP, Roth MD, Clements PJ, et al. Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016; 4(9): 708–719.
  87. Kreuter M, Ladner UM, Costabel U, et al. The diagnosis and treatment of pulmonary fibrosis. Dtsch Arztebl Int. 2021 [Epub ahead of print]; 118(Forthcoming).
  88. Morisset J, Johannson KA, Vittinghoff E, et al. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest. 2017; 151(3): 619–625.
  89. De Sadeleer LJ, Hermans F, De Dycker E, et al. Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. J Clin Med. 2018; 8(1).
  90. Adegunsoye A, Oldham JM, Fernández Pérez ER, et al. Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Res. 2017; 3(3).
  91. Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020; 383(10): 958–968.
  92. Selman M, Pardo A. From pulmonary fibrosis to progressive pulmonary fibrosis: a lethal pathobiological jump. Am J Physiol Lung Cell Mol Physiol. 2021; 321(3): L600–L607.
  93. Maher TM, Brown KK, Kreuter M, et al. INBUILD trial investigators. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease. Eur Respir J. 2022; 59(2).
  94. Valenzuela C, Maher T, Bonella F, et al. Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial. ILD / DPLD of known origin. 2020.
  95. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171(9): 1040–1047.
  96. King TE, Bradford WZ, Castro-Bernardini S, et al. ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22): 2083–2092.
  97. Noble P, Albera C, Bradford W, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. The Lancet. 2011; 377(9779): 1760–1769.
  98. Behr J, Prasse A, Kreuter M, et al. RELIEF investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021; 9(5): 476–486.
  99. Home - ClinicalTrials.gov. https://www.clinicaltrials.gov/ (20 grudnia 2021).
  100. Gibson CD, Kugler MC, Deshwal H, et al. Advances in targeted therapy for progressive fibrosing interstitial lung disease. Lung. 2020; 198(4): 597–608.
  101. Wang P, Jones KD, Urisman A, et al. Pathologic findings and prognosis in a large prospective cohort of chronic hypersensitivity pneumonitis. Chest. 2017; 152(3): 502–509.
  102. Raghu G, Anstrom KJ, King TE, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012; 366(21): 1968–1977.
  103. Newton CA, Zhang D, Oldham JM, et al. Telomere length and use of immunosuppressive medications in idiopathic pulmonary Fibrosis. Am J Respir Crit Care Med. 2019; 200(3): 336–347.
  104. Teoh AKY, Corte TJ. Nonspecific interstitial pneumonia. Semin Respir Crit Care Med. 2020; 41(2): 184–201.
  105. Lee J, Kim YH, Kang JiY, et al. Korean Interstitial Lung Diseases Study Group. Korean guidelines for diagnosis and management of interstitial lung diseases: part 3. Idiopathic nonspecific interstitial pneumonia. Tuberc Respir Dis (Seoul). 2019; 82(4): 277–284.
  106. Salisbury ML, Myers JL, Belloli EA, et al. Diagnosis and treatment of fibrotic hypersensitivity pneumonia. Where we stand and where we need to go. Am J Respir Crit Care Med. 2017; 196(6): 690–699.
  107. Goos T, De Sadeleer LJ, Yserbyt J, et al. Progression in the management of non-idiopathic pulmonary fibrosis interstitial lung diseases, where are we now and where we would like to be. J Clin Med. 2021; 10(6).
  108. Cottin V, Inoue Y, Kolb M, et al. Effect of nintedanib on FVC decline in patients with progressive fibrosing ILDs: data from the INBUILD trial. C22. ILD THERAPY III. 2020.
  109. Ley B, Bradford WZ, Vittinghoff E, et al. Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016; 194(6): 711–718.
  110. Nathan SD, Albera C, Bradford WZ, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016; 71(5): 429–435.
  111. Richeldi L, Crestani B, Azuma A, et al. Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib. Respir Med. 2019; 156: 20–25.
  112. Jastrzebski D, Gumola A, Gawlik R, et al. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J Physiol Pharmacol Off J Pol Physiol Soc. 2006; 57(Suppl 4): 139–148.
  113. Vainshelboim B, Oliveira J, Yehoshua L, et al. Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. Respiration. 2014; 88(5): 378–388.
  114. Vainshelboim B, Oliveira J, Fox BD, et al. Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. Lung. 2015; 193(3): 345–354.
  115. Vainshelboim B, Kramer MR, Fox BD, et al. Supervised exercise training improves exercise cardiovascular function in idiopathic pulmonary fibrosis. Eur J Phys Rehabil Med. 2017; 53(2): 209–218.
  116. Devani P, Pinto N, Jain P, et al. Effect of pulmonary rehabilitation (PR) program in patients with interstitial lung disease (ILD)-Indian scenario. J Assoc Physicians India. 2019; 67(3): 28–33.
  117. Dowman LM, McDonald CF, Hill CJ, et al. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. Thorax. 2017; 72(7): 610–619.
  118. Holland AE, Dowman LM, Hill CJ. Principles of rehabilitation and reactivation: interstitial lung disease, sarcoidosis and rheumatoid disease with respiratory involvement. Respiration. 2015; 89(2): 89–99.
  119. Pettersson H, Alexanderson H, Poole JL, et al. Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS). Best Pract Res Clin Rheumatol. 2021; 35(3): 101695.
  120. Ryerson CJ, Cayou C, Topp F, et al. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. Respir Med. 2014; 108(1): 203–210.
  121. Tonelli R, Cocconcelli E, Lanini B, et al. Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: a multicenter prospective study. BMC Pulm Med. 2017; 17(1): 130.
  122. Holland AE, Hill CJ, Glaspole I, et al. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir Med. 2012; 106(3): 429–435.
  123. Brunetti G, Malovini A, Maniscalco M, et al. Pulmonary rehabilitation in patients with interstitial lung diseases: Correlates of success. Respir Med. 2021; 185: 106473.
  124. Dowman L, Hill CJ, May A, et al. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2021; 2: CD006322.
  125. Khor YH, Holland AE, Goh NSL, et al. Ambulatory oxygen in fibrotic interstitial lung disease: A pilot, randomized, triple-blinded, sham-controlled trial. Chest. 2020; 158(1): 234–244.
  126. Visca D, Mori L, Tsipouri V, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med. 2018; 6(10): 759–770.
  127. Bajwah S, Higginson IJ, Ross JR, et al. The palliative care needs for fibrotic interstitial lung disease: a qualitative study of patients, informal caregivers and health professionals. Palliat Med. 2013; 27(9): 869–876.
  128. Bajwah S, Yorke J. Palliative care and interstitial lung disease. Curr Opin Support Palliat Care. 2017; 11(3): 141–146.
  129. Kreuter M, Bendstrup E, Russell AM, et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med. 2017; 5(12): 968–980.
  130. Weill D. Lung transplantation: indications and contraindications. J Thorac Dis. 2018; 10(7): 4574–4587.

Regulamin

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

Wydawcą serwisu jest VM Media Group sp. z o.o, Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl